China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced plans to invest RMB130 million (USD17.9 million) in compatriot firm Shenzhen GeneMind Biosciences Co., Ltd., a gene sequencer specialist. This investment aims to enhance Sansure’s industry chain layout in the gene sequencing sector and boost its comprehensive competitiveness.
Transaction Details
The transaction includes the acquisition of partial equity in GeneMind, increasing Sansure’s stakes in GeneMind from 11.903047% to 15.549381%. This strategic investment underscores Sansure’s commitment to expanding its presence in the gene sequencing market.
GeneMind’s Technology and Focus
GeneMind specializes in the research and manufacturing of upstream equipment and reagents for the gene sequencing industry. The company possesses advanced technologies in fluorescence detection, nucleic acid modification, dye synthesis, enzyme mutation, surface chemical processes, and other key areas.-Fineline Info & Tech
Leave a Reply